Lineage Cell Therapeutics

LCTX

Market cap $394M

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today announced the receipt of a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits, from Factor Bioscience Inc. (“Factor”). Generation of the line marks a successful milestone in the strategic collaboration between the two companies, un.

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today published a letter to shareholders highlighting the company's achievements throughout 2025 and its corporate outlook for 2026. To Our Shareholders: As we conclude a successful 2025, I want to extend my appreciation for your continued support of Lineage Cell T.

Lineage Cell Therapeutics' OpRegen is partnered with Genentech/Roche. In my view, this is their main value driver in GA dry AMD. Looking ahead, their GAlette Phase 2a trial is enrolling, which could further validate the rest of their portfolio's potential. LCTX's pipeline also has OPC1 for spinal cord injury. Its preclinical R&D includes ANP1, PNC1, RND1, and ILT1.

Lineage Cell Therapeutics, Inc. ( LCTX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Ioana Hone - Director of Investor Relations Brian Culley - CEO, President & Director Jill Howe - CFO & Principal Financial and Accounting Officer Conference Call Participants William Wood - B. Riley Securities, Inc., Research Division Joseph Pantginis - H.C.

Lineage Cell (LCTX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today reported its third quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. “It has been a productive third quarter for the Lineage team,” stated Brian.

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 6, 2025, at.

Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 11:30 AM EDT Company Participants Brian Culley - CEO, President & Director Conference Call Participants Sara Nik - H.C.

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the initiation of a new islet cell transplant program in Type 1 Diabetes (T1D). Specifically, the company aims to deploy its manufacturing capability to address the issue of large-scale production of islet cells, with the initial goal of establishin.

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neurological and ophthalmic conditions, today announced that Brian M. Culley, Lineage's Chief Executive Officer, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference, on September 8, 2025, at 11:30am ET and at Baird's 2025 Global Healthcare Conference, on.